SAN FRANCISCO and HOLLISTON, Mass., Dec. 30, 2015 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced that its CEO Jim McGorry will present at the 8th annual Biotech Showcase conference on Monday, January 11th at 2:00 pm. Pacific Time. Mr. McGorry, Dr. Saverio La Francesca, HART's Chief Medical Officer, and Tom McNaughton, HART's CFO, will also be available for investment community meetings in San Francisco Monday, January 11th through Wednesday, January 13th - contact investor relations (below) to schedule a meeting.
HART's presentation audio and slides will be webcast live and available for replay. The conference will be held at the Parc 55 Hotel in San Francisco, CA.
Live Webcast/Replay: http://edge.media-server.com/m/p/dfrf568n
About Biotech Showcase™ (http://www.ebdgroup.com/bts/index.php) Biotech Showcase™ is an investor and networking conference providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and industry executives in one place during the course of one of the largest annual gatherings of healthcare investors. Now in its eighth year, Biotech Showcase 2016 is expected to attract upwards of 2,100 attendees.
About HART (http://www.harvardapparatusregen.com) Harvard Apparatus Regenerative Technology (HART) makes bioengineered implants for life-threatening conditions. Our technology platform is to be used to restore function in the esophagus and the trachea and bronchus airways. Our first generation tracheal implant has been used successfully in five adult human implant procedures approved under compassionate use exemptions, but none of our products are yet approved for marketing by a government regulatory authority. HART is completing further large-animal studies to refine our technology platform with the goals of pursuing one or more compassionate use implantation surgeries and filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in 2016, seeking to initiate clinical trials for one of our three product candidates.
Harvard Apparatus Regenerative Technology, Inc. Tom McNaughton Chief Financial Officer 774-233-7321
Catalyst Global LLC David Collins, Tanya Kamatu 212-924-9800 firstname.lastname@example.org
SOURCE Harvard Apparatus Regenerative Technology, Inc.